Gilead Reports Results of Selonsertib in P-III STELLAR-4 study for Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

Gilead Reports Results of Selonsertib in P-III STELLAR-4 study for Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

Shots:

  • The P-III STELLAR-4 study involves assessing of Selonsertib (18mg, 6mg, qd) vs PBO (qd) in patients with compensated cirrhosis (F4) due to NASH for 240 wks.
  • The P-III study didn’t meet its 1EPs @48wks., achieved a ≥ 1-stage improvement in fibrosis (14.4%, 12.5% or 12.8%) and was well-tolerated with safe results
  • Selonsertib is qd an oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), evaluated in P-II ATLAS study in combination with cilofexor (GS-9674) and firsocostat (GS-0976) for advanced fibrosis due to NASH

Click here to read full press release/ article | Ref: Gilead | Image: HIVPlusMag